Stem Cells From A New Source For The Treatment Of The Heart

Stem Cells From A New Source For The Treatment Of The Heart.
Stem cells from the amniotic sac that surrounds a fetus may someday be old to renewal impair caused by a heart attack, Japanese researchers report. The work, so far only conducted in animals, raises the feasibility of a non-controversial source of stem cells to expound not only heart disease but also many other conditions, said Dr Shunichiro Miyoshi, an assistant professor in the cardiology subdivision at the Keio University School of Medicine, and co-author of a report in the May 28 online dissemination of Circulation Research. "I believe these cells may be utilized in the treatment of autoimmune diseases such as SLA systemic lupus erythematosus and rheumatoid arthritis".

The amniotic sac is typically discarded after childbirth. SLA is an autoimmune disability in which the body's exempt system cells mistakenly seize healthy tissue. The cells that Miyoshi and his colleagues have used in mouse studies can simply be obtained in large numbers and offer another major advantage: they bypass the need to match donor-recipient apartment typing.

So "At the present time there is no barrier for clinical utilization. We can secure amniotic membrane from every delivery. We do not need to match donor-recipient matching of complicated HLA typing". HLA refers to the protein markers that are found on most of the body's cells. Transplanted cells that be at variance from the recipient's HLA quintessence will be attacked and destroyed by the immune system.

The Keio researchers have begun a series of studies aimed at the good-natured use of the amniotic stem cells. "Now we are performing the test on a swine model. Immediately after we get a good result, we are planning to perform clinical trials. I maintain it will go on within a few years. But it may depend on the strength of our government regulation".

The journal report describes laboratory make in which stem cells obtained from amniotic membranes were transformed into heart cells, 33 percent of which form spontaneously and which improved rat heart function by more than 34 percent when injected two weeks after a insensitivity attack. The injected cells decreased the room of heart damage by 13 percent to 18 percent and survived for more than four weeks in the rats without the use of drugs to run-in immune rejection. The amniotic cells are much easier to convert into kindness cells than stem cells from other sources, such as bone marrow or fat.

They probably can be converted just as easily to cells of rare organs. The immunological neutrality of the cells is "quite fascinating or mysterious". One theory is that the amniotic sac bars the insusceptible systems of the mother-to-be and her fetus from attacking each other by not producing the HLA proteins that associate foreign tissue.

A number of studies using stem cells to renew heart damage are ongoing in the United States, said Dr Douglas W Losordo, head of the Feinberg Cardiovascular Research Institute. Most studies have tried to use cells from the patient's own tissue, such as bone marrow.

So "There have been lots of coarse studies and preliminary studies in patients needle-shaped at repairing damage in heart attacks. There have been many discussions about whether some cells are better than others, and what sources of cells are available".

The Japanese broadcast will get attention because "the fact that a source of cells is gladly available is of immediate interest". Laboratory studies have indicated that stem cells from younger commonality have a greater ability to be transformed to cells of specific tissues. "It makes intuitive judgement that cells from the amniotic membrane may enjoy a potency advantage".

But much work is needed to fulfill "the creativity outcome - someone comes in with a heart attack and you have these cells sitting on the shelf that you can insert to repair the heart". The Japanese report is potentially very important for several reasons, said Dr Marc S Penn, maestro of the Cleveland Clinics Skirball Laboratory for Cardiovascular Cellular Therapy, and co-author of an accompanying editorial.

It is a best-seller adult's stem cell group that can be delivered allogenically, from one person to another. It might be possible to deliver it when a patient is having an artery opened in therapy for a heart attack. These cells appear to differentiate into true cardiac muscle cells, and there's not pure evidence that others do. The key is that this needs to be repeated by another group prozac 30 mg side effects. But at in the first place blush it appears to be an important finding.